[go: up one dir, main page]

NO20074661L - Use of a compound - Google Patents

Use of a compound

Info

Publication number
NO20074661L
NO20074661L NO20074661A NO20074661A NO20074661L NO 20074661 L NO20074661 L NO 20074661L NO 20074661 A NO20074661 A NO 20074661A NO 20074661 A NO20074661 A NO 20074661A NO 20074661 L NO20074661 L NO 20074661L
Authority
NO
Norway
Prior art keywords
compound
desmethoxyrapamycin
och
medicament
disease
Prior art date
Application number
NO20074661A
Other languages
Norwegian (no)
Inventor
Matthew Alan Gregory
Rose Mary Sheridan
Mingqiang Zhang
Original Assignee
Biotica Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0504995.2A external-priority patent/GB0504995D0/en
Priority claimed from GB0522829A external-priority patent/GB0522829D0/en
Application filed by Biotica Tech Ltd filed Critical Biotica Tech Ltd
Publication of NO20074661L publication Critical patent/NO20074661L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Anvendelse av en 39-desmetoksyrapamycinanalog med formelen der R, representerer (H, H) eller =0 og R, og Rhver uavhengig representerer H, OH eller OCH; eller et farmasøytisk akseptabelt salt av samme, i framstilling av et medikament for behandling av en medisinsk tilstand som resulterer fra nerveskade eller sykdom.Use of a 39-desmethoxyrapamycin analog of the formula wherein R 1 represents (H, H) or = O and R, and R 1r independently represents H, OH or OCH; or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a medical condition resulting from nerve damage or disease.

NO20074661A 2005-03-11 2007-09-13 Use of a compound NO20074661L (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0504995.2A GB0504995D0 (en) 2005-03-11 2005-03-11 Use of a compound
US11/097,605 US7183289B2 (en) 2005-03-11 2005-04-01 39-desmethoxyrapamycin, compositions and methods of use thereof
GB0522829A GB0522829D0 (en) 2005-11-09 2005-11-09 Use of a compound
PCT/GB2006/000834 WO2006095173A2 (en) 2005-03-11 2006-03-10 Medical uses of 39-desmethoxyrapamycin and analogues thereof

Publications (1)

Publication Number Publication Date
NO20074661L true NO20074661L (en) 2007-10-30

Family

ID=36659697

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074661A NO20074661L (en) 2005-03-11 2007-09-13 Use of a compound

Country Status (6)

Country Link
EP (1) EP1896018A2 (en)
KR (1) KR20070116868A (en)
AU (1) AU2006221774A1 (en)
CA (1) CA2599547A1 (en)
NO (1) NO20074661L (en)
WO (1) WO2006095173A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
WO2017040341A1 (en) * 2015-08-28 2017-03-09 Buck Institute For Research On Aging RAPAMYCIN ANALOGS SHOWING IMPROVED mTORC1 SPECIFICITY
CN111760015A (en) * 2020-01-21 2020-10-13 中南大学 Application of micafungin in the preparation of neuroprotective drugs
CN118767105B (en) * 2024-07-11 2025-05-09 首都医科大学宣武医院 Use of anidulafungin for preventing and treating neurodegenerative diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5432183A (en) 1991-05-31 1995-07-11 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
SG64372A1 (en) 1993-12-17 1999-04-27 Novartis Ag Rapamycin derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
AU712193B2 (en) 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
NZ333657A (en) 1996-07-30 2000-05-26 Novartis Ag A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
JP2005532809A (en) * 2002-07-16 2005-11-04 バイオチカ テクノロジー リミテッド Manufacture of polyketides and other natural products
GB0417852D0 (en) * 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds

Also Published As

Publication number Publication date
EP1896018A2 (en) 2008-03-12
AU2006221774A1 (en) 2006-09-14
WO2006095173A3 (en) 2007-01-11
WO2006095173A2 (en) 2006-09-14
KR20070116868A (en) 2007-12-11
CA2599547A1 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
MX2009006742A (en) Novel compounds.
CY1115719T1 (en) NEW PHARMACEUTICAL COMBINATIONS FOR THE RESPIRATORY DISEASE TREATMENT
AR109170A2 (en) ACID SPHINGOMYELINASE FOR USE IN THE PREVENTION OR TREATMENT OF NIEMANN-PICK A OR B DISEASE IN A PATIENT
UY27092A1 (en) DERIVATIVES OF THE NEW QUINUCLIDINE CARBAMATE AND THE MEDICINAL COMPOSITIONS CONTAINING THEM
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
MY149622A (en) Pyrazoles as 11-beta-hsd-1
NO20082643L (en) Isoquinolinaminopyrazole derivatives, their preparation and use as pharmaceutical agents for the treatment of cancer
NO20081315L (en) Benzokinazoline derivatives and their use in the treatment of bone disorders
NO20065904L (en) Therapeutic compounds
WO2008020040A3 (en) 2,5-dihydroxybenzene compounds for the treatment of fibrosis
UA107578C2 (en) COMBINED DIABETES THERAPY
UA83233C2 (en) Substituted 2-aminotetralin for the treatment of depression
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
MX2007012212A (en) Pyrazoles.
EA200601837A1 (en) PETROXASES FOR TREATMENT OF RESPIRATORY DISEASES
UY29085A1 (en) PIRIMIDINE DERIVATIVES 4-SULFONAMID SUBSTITUTED, INTERMEDIATE COMPOUNDS FOR PREPARATION, PREPARATION PROCEDURES, MEDICINAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
NO20064010L (en) Indazole derivatives and pharmaceutical preparations contain such
NO20074661L (en) Use of a compound
NO20083790L (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
EA200602016A1 (en) POWDER COMPOSITIONS FOR INHALATION CONTAINING ENANTIOMERNA CLEAN AGENTISTS
WO2009084834A3 (en) Pharmaceutical composition for the treatment and prevention of cardiac disease
DK1814848T3 (en) 2,3,4-substituted-cyclopentanones as therapeutic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application